December 10th 2024EP. 5: Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections The panelist discusses Rebyota, a treatment approved by the FDA for preventing ...

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut ...

Clostridioides difficile is a type of bacteria that often affects people who have been taking antibiotics, GST Micro LLC ...

The following is a summary of “Oral Capsule FMT Combined With Bezlotoxumab Is a Successful Rescue Protocol Following Failure ...

Clostridium difficile infection (CDI ... Although metronidazole and vancomycin are and have been the mainstay treatment options for CDI, there are some unmet medical and therapeutical needs.

Pharmaceuticals announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA ...

Dan Ilges [Opens in a new window], ...

Purpose: Current and future treatment modalities for Clostridium difficile-associated disease (CDAD) are reviewed. Conclusion: CDAD is a major concern for health care systems and clinicians.

The product is based on purified Firmicutes bacterial spores delivered in an oral capsule that is designed to encourage the regrowth of healthy bacteria after antibiotic treatment for C.

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

The Company today announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA Communications ... s ability to achieve Clinical Cure of CDI as measured ...

Following the previously announced successful End of Phase 2 Meeting achieving agreement with FDA on non-clinical and clinical Phase 3-readiness, Acurx has now also received written positive feedback ...